RedHill Biopharma Adjourns Shareholder Meeting
Ticker: RDHL · Form: 6-K · Filed: Mar 20, 2024 · CIK: 1553846
| Field | Detail |
|---|---|
| Company | Redhill Biopharma Ltd. (RDHL) |
| Form Type | 6-K |
| Filed Date | Mar 20, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: meeting-adjournment, shareholder-meeting, corporate-governance
Related Tickers: RHBP
TL;DR
RHBP adjourned their shareholder meeting to April 15th, giving more time for proposals.
AI Summary
RedHill Biopharma Ltd. announced the adjournment of its Extraordinary General Meeting of Shareholders, originally scheduled for March 20, 2024. The meeting has been rescheduled to April 15, 2024, at 9:00 AM Israel time, to allow shareholders more time to consider the proposed business. The meeting will be held virtually.
Why It Matters
The adjournment suggests potential complexities or a need for further shareholder engagement on the proposed business, which could impact future corporate decisions or strategies.
Risk Assessment
Risk Level: low — This filing is procedural, announcing a meeting adjournment and rescheduling, with no immediate financial or operational impact disclosed.
Key Players & Entities
- RedHill Biopharma Ltd. (company) — Registrant
- March 20, 2024 (date) — Original meeting date
- April 15, 2024 (date) — Rescheduled meeting date
FAQ
Why was the Extraordinary General Meeting of Shareholders adjourned?
The meeting was adjourned to allow shareholders more time to consider the proposed business.
What is the new date and time for the rescheduled meeting?
The meeting is rescheduled for April 15, 2024, at 9:00 AM Israel time.
How will the rescheduled meeting be conducted?
The meeting will be held virtually.
What is the company's principal executive office address?
The company's principal executive offices are located at 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel.
Does RedHill Biopharma file annual reports under Form 20-F or 40-F?
RedHill Biopharma files annual reports under Form 20-F.
Filing Stats: 377 words · 2 min read · ~1 pages · Grade level 8.6 · Accepted 2024-03-20 16:38:00
Filing Documents
- zk2431174.htm (6-K) — 14KB
- 0001178913-24-001008.txt ( ) — 15KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: March 20, 2024 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer